Adline Chem Lab Ltd.

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, MEDPLUS.NS has a market cap of 108.4B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while MEDPLUS.NS trades at ₹903.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas MEDPLUS.NS's P/E ratio is 52.29. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is less volatile compared to MEDPLUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDPLUS.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, MEDPLUS.BO has a market cap of 108.4B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while MEDPLUS.BO trades at ₹903.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas MEDPLUS.BO's P/E ratio is 52.29. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is less volatile compared to MEDPLUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDPLUS.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, GUJTHEM.BO has a market cap of 39.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while GUJTHEM.BO trades at ₹360.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas GUJTHEM.BO's P/E ratio is 82.06. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, ADLINE.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GUJTHEM.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, KPL.BO has a market cap of 16.9B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while KPL.BO trades at ₹1,626.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas KPL.BO's P/E ratio is 29.79. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, ADLINE.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KPL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SHUKRAPHAR.BO has a market cap of 14.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SHUKRAPHAR.BO trades at ₹32.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SHUKRAPHAR.BO's P/E ratio is -163.10. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, ADLINE.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SHUKRAPHAR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, FREDUN.BO has a market cap of 11.4B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while FREDUN.BO trades at ₹2,119.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas FREDUN.BO's P/E ratio is 30.32. In terms of profitability, ADLINE.BO's ROE is N/A, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, ADLINE.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check FREDUN.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ACCENTMIC.NS has a market cap of 10.5B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ACCENTMIC.NS trades at ₹436.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ACCENTMIC.NS's P/E ratio is 29.36. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to ACCENTMIC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ACCENTMIC.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SASTASUNDR.BO has a market cap of 8.7B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SASTASUNDR.BO trades at ₹272.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SASTASUNDR.BO's P/E ratio is 33.21. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, ADLINE.BO is less volatile compared to SASTASUNDR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SASTASUNDR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SASTASUNDR.NS has a market cap of 8.5B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SASTASUNDR.NS trades at ₹268.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SASTASUNDR.NS's P/E ratio is 32.86. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, ADLINE.BO is less volatile compared to SASTASUNDR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SASTASUNDR.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, BPLPHARMA.BO has a market cap of 8.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while BPLPHARMA.BO trades at ₹1,208.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas BPLPHARMA.BO's P/E ratio is -28.22. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BPLPHARMA.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ANUHPHR.BO has a market cap of 8.1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ANUHPHR.BO trades at ₹80.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ANUHPHR.BO's P/E ratio is 19.39. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, ADLINE.BO is less volatile compared to ANUHPHR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ANUHPHR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, REMUS.NS has a market cap of 7.4B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while REMUS.NS trades at ₹631.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas REMUS.NS's P/E ratio is 17.63. In terms of profitability, ADLINE.BO's ROE is N/A, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to REMUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check REMUS.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SUDARSHAN.BO has a market cap of 7.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SUDARSHAN.BO trades at ₹30.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SUDARSHAN.BO's P/E ratio is 36.06. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SUDARSHAN.BO's ROE of +0.15%. Regarding short-term risk, ADLINE.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SUDARSHAN.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PRAVEG.BO has a market cap of 7.2B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PRAVEG.BO trades at ₹274.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PRAVEG.BO's P/E ratio is -187.74. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PRAVEG.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SGRL.BO has a market cap of 6.7B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SGRL.BO trades at ₹518.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SGRL.BO's P/E ratio is 36.79. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, ADLINE.BO is less volatile compared to SGRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SGRL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ALBERTDA.BO's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ALBERTDA.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, VIKRAMTH.BO has a market cap of 4.8B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while VIKRAMTH.BO trades at ₹152.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas VIKRAMTH.BO's P/E ratio is 14.05. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, ADLINE.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VIKRAMTH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, JENBURPH.BO has a market cap of 4.6B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while JENBURPH.BO trades at ₹1,051.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas JENBURPH.BO's P/E ratio is 14.30. In terms of profitability, ADLINE.BO's ROE is N/A, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, ADLINE.BO is less volatile compared to JENBURPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check JENBURPH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, INFINIUM.NS has a market cap of 3.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while INFINIUM.NS trades at ₹210.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas INFINIUM.NS's P/E ratio is 34.83. In terms of profitability, ADLINE.BO's ROE is N/A, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to INFINIUM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check INFINIUM.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TLL.BO has a market cap of 3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TLL.BO trades at ₹252.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TLL.BO's P/E ratio is 20.29. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, ADLINE.BO is less volatile compared to TLL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TLL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ZENOTECH.BO trades at ₹45.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ZENOTECH.BO's P/E ratio is 82.73. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENOTECH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, KERALAYUR.BO has a market cap of 2.8B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while KERALAYUR.BO trades at ₹229.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas KERALAYUR.BO's P/E ratio is -11.71. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, ADLINE.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KERALAYUR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, AMBALALSA.BO has a market cap of 2.7B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while AMBALALSA.BO trades at ₹35.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas AMBALALSA.BO's P/E ratio is 25.87. In terms of profitability, ADLINE.BO's ROE is N/A, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to AMBALALSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check AMBALALSA.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, GENNEX.BO has a market cap of 2.5B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while GENNEX.BO trades at ₹10.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas GENNEX.BO's P/E ratio is 14.19. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, ADLINE.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GENNEX.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SYSCHEM.BO trades at ₹50.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SYSCHEM.BO's P/E ratio is 34.36. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SYSCHEM.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, BDH.BO has a market cap of 2.2B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while BDH.BO trades at ₹374.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas BDH.BO's P/E ratio is 20.70. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, ADLINE.BO is less volatile compared to BDH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BDH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, OXYGENTAPH.BO has a market cap of 2.1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while OXYGENTAPH.BO trades at ₹57.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas OXYGENTAPH.BO's P/E ratio is -12.21. In terms of profitability, ADLINE.BO's ROE is N/A, compared to OXYGENTAPH.BO's ROE of +0.58%. Regarding short-term risk, ADLINE.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check OXYGENTAPH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TRANSCHEM.BO has a market cap of 2.1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TRANSCHEM.BO trades at ₹169.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TRANSCHEM.BO's P/E ratio is 70.27. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to TRANSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TRANSCHEM.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, QUESTLAB.NS has a market cap of 2.1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while QUESTLAB.NS trades at ₹125.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas QUESTLAB.NS's P/E ratio is 15.18. In terms of profitability, ADLINE.BO's ROE is N/A, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to QUESTLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check QUESTLAB.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SANJIVIN.BO has a market cap of 2.1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SANJIVIN.BO trades at ₹167.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SANJIVIN.BO's P/E ratio is 25.38. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SANJIVIN.BO's ROE of +0.20%. Regarding short-term risk, ADLINE.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SANJIVIN.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PARNAXLAB.BO has a market cap of 1.8B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PARNAXLAB.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PARNAXLAB.BO's P/E ratio is 14.77. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, ADLINE.BO is less volatile compared to PARNAXLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PARNAXLAB.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, KIMIABL.BO has a market cap of 1.7B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while KIMIABL.BO trades at ₹36.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KIMIABL.BO's ROE of +0.92%. Regarding short-term risk, ADLINE.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KIMIABL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while NATCAPSUQ.BO trades at ₹158.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas NATCAPSUQ.BO's P/E ratio is -8.57. In terms of profitability, ADLINE.BO's ROE is N/A, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, ADLINE.BO and NATCAPSUQ.BO have similar daily volatility (0.00).Check NATCAPSUQ.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PANCHSHEEL.BO has a market cap of 1.6B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PANCHSHEEL.BO trades at ₹120.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PANCHSHEEL.BO's P/E ratio is 13.23. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, ADLINE.BO is less volatile compared to PANCHSHEEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PANCHSHEEL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, AUROLAB.BO has a market cap of 1.6B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while AUROLAB.BO trades at ₹250.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas AUROLAB.BO's P/E ratio is 48.17. In terms of profitability, ADLINE.BO's ROE is N/A, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, ADLINE.BO is less volatile compared to AUROLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check AUROLAB.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, CORALAB.BO has a market cap of 1.5B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while CORALAB.BO trades at ₹426.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas CORALAB.BO's P/E ratio is 10.91. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, ADLINE.BO is less volatile compared to CORALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CORALAB.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, LACTOSE.BO has a market cap of 1.4B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while LACTOSE.BO trades at ₹113.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas LACTOSE.BO's P/E ratio is 29.27. In terms of profitability, ADLINE.BO's ROE is N/A, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to LACTOSE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check LACTOSE.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SMRUTHIORG.BO trades at ₹117.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SMRUTHIORG.BO's P/E ratio is 29.30. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, ADLINE.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SMRUTHIORG.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SOTAC.NS has a market cap of 1.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SOTAC.NS trades at ₹117.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SOTAC.NS's P/E ratio is 15.12. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to SOTAC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SOTAC.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TYCHE.BO has a market cap of 1.3B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TYCHE.BO trades at ₹122.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TYCHE.BO's P/E ratio is 18.44. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to TYCHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TYCHE.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, DENISCHEM.BO has a market cap of 1.1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while DENISCHEM.BO trades at ₹76.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas DENISCHEM.BO's P/E ratio is 12.26. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check DENISCHEM.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PHARMAID.BO has a market cap of 1B. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PHARMAID.BO trades at ₹29.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PHARMAID.BO's P/E ratio is -5.79. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, ADLINE.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PHARMAID.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, MAKERSL.BO has a market cap of 880.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while MAKERSL.BO trades at ₹149.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas MAKERSL.BO's P/E ratio is 72.43. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MAKERSL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, GODAVARI.BO has a market cap of 868.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while GODAVARI.BO trades at ₹115.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas GODAVARI.BO's P/E ratio is -126.71. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GODAVARI.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, MERCURYLAB.BO has a market cap of 855.8M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while MERCURYLAB.BO trades at ₹713.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas MERCURYLAB.BO's P/E ratio is 18.14. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, ADLINE.BO is less volatile compared to MERCURYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MERCURYLAB.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, CONCORD.BO has a market cap of 845.5M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while CONCORD.BO trades at ₹84.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas CONCORD.BO's P/E ratio is 193.11. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CONCORD.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SOURCENTRL.BO has a market cap of 835.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SOURCENTRL.BO trades at ₹129.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SOURCENTRL.BO's P/E ratio is 29.97. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SOURCENTRL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, BACPHAR.BO has a market cap of 804.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while BACPHAR.BO trades at ₹56.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas BACPHAR.BO's P/E ratio is 112.06. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BACPHAR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, BIBCL.BO has a market cap of 763M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while BIBCL.BO trades at ₹17.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas BIBCL.BO's P/E ratio is -4.84. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ADLINE.BO is less volatile compared to BIBCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BIBCL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PHRMASI.BO has a market cap of 744.1M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PHRMASI.BO trades at ₹109.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PHRMASI.BO's P/E ratio is 4.19. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, ADLINE.BO is less volatile compared to PHRMASI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PHRMASI.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ZENITHDRUG.NS has a market cap of 741.7M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ZENITHDRUG.NS trades at ₹43.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ZENITHDRUG.NS's P/E ratio is 10.35. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENITHDRUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENITHDRUG.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SUNLOC.BO has a market cap of 635.8M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SUNLOC.BO trades at ₹62.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SUNLOC.BO's P/E ratio is 22.22. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to SUNLOC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SUNLOC.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, VILINBIO.NS has a market cap of 512M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while VILINBIO.NS trades at ₹36.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas VILINBIO.NS's P/E ratio is 229.38. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO and VILINBIO.NS have similar daily volatility (0.00).Check VILINBIO.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, VISTAPH.BO has a market cap of 490M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while VISTAPH.BO trades at ₹7.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas VISTAPH.BO's P/E ratio is -6.08. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, ADLINE.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VISTAPH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PANJON.BO has a market cap of 436M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PANJON.BO trades at ₹25.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PANJON.BO's P/E ratio is 101.60. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PANJON.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ROOPAIND.BO has a market cap of 434.4M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ROOPAIND.BO trades at ₹55.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ROOPAIND.BO's P/E ratio is 22.45. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, ADLINE.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ROOPAIND.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, VRL.BO has a market cap of 431.8M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while VRL.BO trades at ₹135.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas VRL.BO's P/E ratio is 11.54. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VRL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SANDUPHQ.BO has a market cap of 423.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SANDUPHQ.BO trades at ₹43.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SANDUPHQ.BO's P/E ratio is 20.76. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to SANDUPHQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SANDUPHQ.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, MEDIORG.NS has a market cap of 407.5M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while MEDIORG.NS trades at ₹29.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas MEDIORG.NS's P/E ratio is 7.98. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO and MEDIORG.NS have similar daily volatility (0.00).Check MEDIORG.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, VEERHEALTH.BO has a market cap of 404.6M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while VEERHEALTH.BO trades at ₹20.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas VEERHEALTH.BO's P/E ratio is 50.58. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to VEERHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VEERHEALTH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ANG.BO has a market cap of 398.4M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ANG.BO trades at ₹30.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ANG.BO's P/E ratio is -3.39. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, ADLINE.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ANG.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SHELTER.BO has a market cap of 357.6M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SHELTER.BO trades at ₹30.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SHELTER.BO's P/E ratio is 5.72. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SHELTER.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SHELTER.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, MEDICAPQ.BO has a market cap of 355.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while MEDICAPQ.BO trades at ₹28.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas MEDICAPQ.BO's P/E ratio is -8.14. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDICAPQ.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, GUJTERC.BO has a market cap of 294.1M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while GUJTERC.BO trades at ₹37.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas GUJTERC.BO's P/E ratio is -20.19. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, ADLINE.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GUJTERC.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, CRSTCHM.BO has a market cap of 287.9M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while CRSTCHM.BO trades at ₹95.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas CRSTCHM.BO's P/E ratio is 12.93. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, ADLINE.BO is less volatile compared to CRSTCHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CRSTCHM.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, DECCAN.BO has a market cap of 276.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while DECCAN.BO trades at ₹11.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas DECCAN.BO's P/E ratio is 12.13. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check DECCAN.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TRIMURTHI.BO's ROE of +0.03%. Regarding short-term risk, ADLINE.BO and TRIMURTHI.BO have similar daily volatility (0.00).Check TRIMURTHI.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ISHITADR.BO has a market cap of 241.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ISHITADR.BO trades at ₹80.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ISHITADR.BO's P/E ratio is 27.18. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to ISHITADR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ISHITADR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ASRL.BO has a market cap of 205.8M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ASRL.BO trades at ₹7.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ASRL.BO's P/E ratio is 19.13. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ASRL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CHEMOPH.BO's ROE of -0.93%. Regarding short-term risk, ADLINE.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CHEMOPH.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ZENITHHE.BO has a market cap of 170.4M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ZENITHHE.BO trades at ₹3.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ZENITHHE.BO's P/E ratio is 39.63. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENITHHE.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SUNREST.NS has a market cap of 157.9M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SUNREST.NS trades at ₹36.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SUNREST.NS's P/E ratio is 7.88. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO and SUNREST.NS have similar daily volatility (0.00).Check SUNREST.NS's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, NORRIS.BO has a market cap of 150M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while NORRIS.BO trades at ₹15.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ADLINE.BO's ROE is N/A, compared to NORRIS.BO's ROE of +0.06%. Regarding short-term risk, ADLINE.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check NORRIS.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, ZENLABS.BO has a market cap of 139.8M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while ZENLABS.BO trades at ₹21.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas ZENLABS.BO's P/E ratio is -7.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENLABS.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, EMMESSA.BO has a market cap of 135.7M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while EMMESSA.BO trades at ₹27.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas EMMESSA.BO's P/E ratio is 42.44. In terms of profitability, ADLINE.BO's ROE is N/A, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check EMMESSA.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, CHCL.BO has a market cap of 125.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while CHCL.BO trades at ₹5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, ADLINE.BO is less volatile compared to CHCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CHCL.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PARMAX.BO has a market cap of 119.6M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PARMAX.BO trades at ₹31.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PARMAX.BO's P/E ratio is -2.36. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PARMAX.BO's ROE of +1.49%. Regarding short-term risk, ADLINE.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PARMAX.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, COLINZ.BO has a market cap of 118.1M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while COLINZ.BO trades at ₹46.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas COLINZ.BO's P/E ratio is 23.92. In terms of profitability, ADLINE.BO's ROE is N/A, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to COLINZ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check COLINZ.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, SHAMROIN.BO has a market cap of 116.1M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while SHAMROIN.BO trades at ₹21.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas SHAMROIN.BO's P/E ratio is -11.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SHAMROIN.BO's ROE of -0.73%. Regarding short-term risk, ADLINE.BO and SHAMROIN.BO have similar daily volatility (0.00).Check SHAMROIN.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TRINITYLEA.BO has a market cap of 111.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TRINITYLEA.BO trades at ₹14.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TRINITYLEA.BO's P/E ratio is -468.67. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to TRINITYLEA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TRINITYLEA.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, BERLDRG.BO has a market cap of 110.1M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while BERLDRG.BO trades at ₹21.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas BERLDRG.BO's P/E ratio is 723.33. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, ADLINE.BO is less volatile compared to BERLDRG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BERLDRG.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, DESHRAK.BO has a market cap of 103.7M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while DESHRAK.BO trades at ₹23.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas DESHRAK.BO's P/E ratio is 32.05. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO and DESHRAK.BO have similar daily volatility (0.00).Check DESHRAK.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, HINDBIO.BO has a market cap of 96.7M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while HINDBIO.BO trades at ₹9.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas HINDBIO.BO's P/E ratio is 62.87. In terms of profitability, ADLINE.BO's ROE is N/A, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, ADLINE.BO is less volatile compared to HINDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check HINDBIO.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, EVOQ.BO has a market cap of 94.4M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while EVOQ.BO trades at ₹3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas EVOQ.BO's P/E ratio is 5.34. In terms of profitability, ADLINE.BO's ROE is N/A, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check EVOQ.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, VIVANZA.BO has a market cap of 84M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while VIVANZA.BO trades at ₹2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas VIVANZA.BO's P/E ratio is -52.50. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, ADLINE.BO is less volatile compared to VIVANZA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VIVANZA.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, DECIPHER.BO has a market cap of 79.3M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while DECIPHER.BO trades at ₹7.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas DECIPHER.BO's P/E ratio is -0.98. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DECIPHER.BO's ROE of -0.37%. Regarding short-term risk, ADLINE.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check DECIPHER.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, KOBO.BO has a market cap of 71.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while KOBO.BO trades at ₹2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas KOBO.BO's P/E ratio is -1.41. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to KOBO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KOBO.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while GANGAPHARM.BO trades at ₹12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO and GANGAPHARM.BO have similar daily volatility (0.00).Check GANGAPHARM.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TIAANC.BO trades at ₹6.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TIAANC.BO's P/E ratio is -62.80. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TIAANC.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, PATIDAR.BO has a market cap of 46.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while PATIDAR.BO trades at ₹8.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas PATIDAR.BO's P/E ratio is -17.50. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, ADLINE.BO and PATIDAR.BO have similar daily volatility (0.00).Check PATIDAR.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, FABINO.BO has a market cap of 40.6M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while FABINO.BO trades at ₹19.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas FABINO.BO's P/E ratio is -26.51. In terms of profitability, ADLINE.BO's ROE is N/A, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO and FABINO.BO have similar daily volatility (0.00).Check FABINO.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, TMTIND-B1.BO has a market cap of 36.2M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while TMTIND-B1.BO trades at ₹7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas TMTIND-B1.BO's P/E ratio is 18.74. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ADLINE.BO and TMTIND-B1.BO have similar daily volatility (0.00).Check TMTIND-B1.BO's competition here

ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADLINE.BO stands at 66M. In comparison, WELCURE.BO has a market cap of 33.7M. Regarding current trading prices, ADLINE.BO is priced at ₹11.28, while WELCURE.BO trades at ₹0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADLINE.BO currently has a P/E ratio of N/A, whereas WELCURE.BO's P/E ratio is 1.30. In terms of profitability, ADLINE.BO's ROE is N/A, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, ADLINE.BO is less volatile compared to WELCURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check WELCURE.BO's competition here